| Martin Olin, EMBA, M.Sc. |
Chief Executive Officer
20 years of executive experience in the pharmaceutical and biotech industry. Before joining Symphogen, Mr. Olin was a senior partner with SLS Invest, a Scandinavian based healthcare focused private equity fund. Prior to joining SLS Invest Mr. Olin held managerial positions in Novo Nordisk including Finance Director, EMEA. Mr. Olin served on the board of Symphogen from 2001 – 2008 and joined as a Chief Financial Officer in 2012. Since September 2016, CEO of Symphogen. Mr. Olin is a Board member of Symphogen and also serves on the board of Ascendis Pharma (public company). Mr. Olin serves as a member of the Lifescience Growth Team appointed by the Danish Government in 2016..
| Ivan D. Horak, MD, FACP |
Head of Global R&D, Chief Scientific and Medical Officer
Prior to joining Symphogen in 2011, Dr. Horak served as President of Research and Development and Chief Scientific Officer of Enzon Pharmaceuticals Inc. Before that, Dr. Horak served as Chief Scientific Officer of Immunomedics, responsible for development of novel antibodies. Dr. Horak has authored over 80 peer-reviewed publications and several book chapters within the fields of hematol- ogy, oncology, and immunology and has served on the editorial boards of several scientific journals. Dr. Horak is a board-certified oncologist. He is a Fellow of the American College of Physicians and a member of the American Association for Cancer Research (AACR), the American Society of Hematology (ASH), and the American Society Clinical Oncology (ASCO).
| Mads Laustsen, M.Sc. |
Chief Manufacturing Officer
| Jesper Bramming, M.Sc. Economics |
Chief Financial Officer